Moderna says COVID-19 vaccine 94.5 percent effective

Andrew Cummings
November 17, 2020

Following fast on the heels of Pfizer's announcement of its COVID-19 vaccine efficacy, Moderna is also sharing positive results from its Phase 3 trial on Monday.

Pfizer's vaccine, which was shown to be more than 90% effective in preventing COVID-19 based on initial data, must be shipped and stored at -70 degrees Celsius (minus 94F), significantly below the standard for vaccines of 2-8 degrees Celsius (36-46F).

The news comes a week after its competitor Pfizer announced that its COVID-19 vaccine, made by Germany's BioNTech, had reached 90% effectiveness, with Russian researchers claiming similar success for its Sputnik V vaccine later that same day. A second group received the actual vaccine, only 5 ended up with the disease. "I'm obviously very happy with the number that we have at 94.5%".

Messenger RNA Technology is a breakthrough way of attacking the virus that's being used for the first time in humans.

This is another very promising sign for the potential of having effective vaccines available to the public in some kind of significant volume at some point next year.

According to her, the submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) is being planned as soon as the required safety milestone is achieved, this is now expected to occur in the third week of November.

Moderna, whose results stem from a clinical trial of more than 30,000 participants, expects to have approximately 20 million doses ready to ship in the United States by year-end.

Other reports by iNewsToday